文献速递眼底病与葡萄膜炎

戊聚糖多硫酸钠暴露与药物诱导性黄斑病变在美国商业保险人群中的关联

Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States.
PubMed 文献 · Ophthalmology · 2019-11-05

结果显示PPS暴露与任何黄斑病变诊断均无显著关联,且无剂量依赖关系。

要点

  • PPS暴露与黄斑病变诊断无显著关联。
  • 未发现PPS累积暴露的剂量依赖关系。
  • 排除糖尿病患者后结果稳定。

核心结论

  • 在该大型商业索赔数据库分析中,未发现PPS暴露与后续黄斑病变诊断存在关联。

研究设计与样本

  • 采用Cox比例风险模型,控制性别、间质性膀胱炎索引诊断时年龄和糖尿病诊断,随访5年或至保险终止或首次黄斑病变诊断。

主要发现

  • 间质性膀胱炎患者中最常见的黄斑病变诊断为渗出性AMD(1.5%)、玻璃膜疣(0.8%)、非渗出性AMD(0.3%)、中毒性黄斑病变(0.1%)和遗传性营养不良(0.04%)。
  • 未调整分析中,填写PPS处方后诊断黄斑病变的患者比例(2.37%)与未填写处方者(2.77%)非常相似。
  • 使用二分类PPS暴露变量的生存模型显示,PPS暴露与玻璃膜疣、非渗出性AMD、渗出性AMD、中毒性黄斑病变、遗传性营养不良或任何黄斑病变的聚合变量诊断均无显著关联。
  • PPS暴露与任何黄斑病变诊断之间无剂量依赖关系。
  • 排除糖尿病患者的敏感性分析模型结果稳定。

临床怎么用

  • 基于该研究,PPS暴露未显示与黄斑病变诊断的显著关联,临床可据此评估用药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the association and cumulative dose-response pattern between pentosan polysulfate sodium (PPS) use for interstitial cystitis (IC) and maculopathy. DESIGN: Large, multicenter, retrospective cohort study of commercially insured patients in the MarketScan database (Truven Health Analytics, San Jose, CA). PARTICIPANTS: Two hundred twenty-seven thousand three hundred twenty-five patients with IC who were enrolled continuously in the MarketScan database. METHODS: Cox proportional hazards models (controlling for patient gender, age at index diagnosis of IC, and diagnosis with diabetes mellitus) followed up patients from index diagnosis of IC for 5 years, or until patients discontinued insurance coverage, or until patients' first diagnosis with a maculopathy. As a sensitivity analysis, we re-estimate all models after excluding all patients with diabetes. To assess for dose response, we calculated the total days of PPS prescriptions filled and created a categorical variable indicating total exposure. MAIN OUTCOME MEASURES: The primary outcome measure was association between binary PPS exposure and any maculopathy. Secondary outcome measures included exposure between binary and categorical, time-dependent, exposure to PPS and to drusen, nonexudative age-related macular degeneration (AMD), exudative AMD, hereditary maculopathy, and toxic maculopathy. RESULTS: The most common diagnoses of maculopathy in patients with IC were exudative AMD (1.5%), drusen (0.8%), nonexudative AMD (0.3%), toxic maculopathy (0.1%), and hereditary dystrophy (0.04%). In unadjusted analyses, the percentage of patients who filled a PPS prescription and were diagnosed later with a maculopathy (2.37%) was very similar to the percentage of patients who did not fill a prescription (2.77%). Survival models using a binary variable indicating PPS exposure showed no significant associations between PPS exposure and diagnosis of drusen, nonexudative AMD, exudative AMD, toxic maculopathy, hereditary dystrophy, or an aggregate variable of any maculopathy. Similarly, there was no dose-dependent relationship between PPS exposure and diagnosis of any maculopathy. These findings remained stable in sensitivity analysis models that excluded patients with diabetes mellitus. CONCLUSIONS: In this large, commercial claims database analysis, no association was found between PPS exposure and subsequent diagnosis of maculopathy.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Ludwig CA, Vail D, Callaway NF, et al. Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States. Ophthalmology. 2019. PMID: 31899034. doi:10.1016/j.ophtha.2019.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。